BTOG's Mission is to support and educate health care professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research. The overall aim is to represent the needs of patients and improve their outcomes.

Opening Message from the Chair – BTOG Steering Committee

I was elected Chair of BTOG Steering Committee in January 2013. BTOG’s growth and development over the last 15 years has been exceptional and the Steering Committee has been integral to this.

Towards the close of this fiscal year BTOG put out a call for applications with a view to convening a new Steering Committee – a combination of old and new members across the multi-disciplinary team. I would like to thank the ‘old’ Steering Committee members for their support, commitment and loyalty to BTOG and for their contribution to the successes so far.

The ‘new’ Steering Committee, Board of Trustees, BTOG Manager and I recognise that there is much more to be done to achieve our vision.

BTOG is now a registered charity and since registering BTOG has been busy putting in place appropriate governance to ensure transparent working and reporting and this is very much an on-going task.

BTOG’s strength is without doubt in its members – healthcare professionals from across all disciplines who make a difference every day to patients with thoracic malignancies. One of our key activities during the 2017/18 year will focus on developing worthwhile on-line membership resources. BTOG will continue to support healthcare professionals in terms of up-to-date and relevant education and in providing a powerful network for research development and collaboration.

BTOG's Vision is to ensure equitable access to optimal care for patients with all thoracic malignancies in the UK and Ireland.
BTOG’s Key Activities

The BTOG Steering Committee represent the multi-disciplinary team, support the aims and objectives of BTOG and take an active role in education and representation.

The BTOG Board of Trustees is responsible for safeguarding the values and purpose of BTOG and ensuring that activities contribute to achieving the objects of the charity and that BTOG follows its legal obligations.

Education

BTOG provides an annual CPD education programme of value in terms of content and registration fees to the whole multi-disciplinary team (MDT) and all programmes are accredited by recognised and relevant bodies.

These events are also accessible to advocates who sit on thoracic oncology clinical studies or trial management groups, advisory boards/groups or other related groups.

Annual Conference:
- The Federation of the Royal Colleges of Physicians of the United Kingdom
- The Royal College of Pathologists
- The Royal College of Surgeons of England
- RCSI Faculty of Radiologists

All Education Events:
- The Federation of the Royal Colleges of Physicians of the United Kingdom
“This was my first BTOG and it is without a doubt the best conference I have attended.
I really enjoyed being at a multi-professional meeting.”

“Very informative, relevant and well-structured sessions demonstrating that much thought and work was devoted prior to delivery.”

“Outstanding conference. Wide range of topics with really high quality speakers.”

“The organisation was brilliant, everything ran smoothly and a lot of thought and hard work had been put into ensuring all needs have been considered.”

“This is a great conference with an organised and lovely group of people.”

“Well organised and executed. A pleasure to attend.”
ASCO 2016 National Update Meeting
10th June 2016 – London

“Very good programme, highly relevant.”

BTOG/NCRI Lung CSG Annual Trials Meeting
Approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 4 category 1 (external) CPD credits (ref 105334)
27th June 2016 – Kensington Close Hotel, Wrights Lane, Kensington, London W8 5SP

“Very interactive and educational.”

BTOG Cachexia Study Day: Definition, clinical implications and treatment
4 CPD Credits approved by the Federation of the Royal Colleges of Physicians of the UK (ref 108478)
25th November 2016 – Wellcome Collection, Euston Road, London

“Well-presented and very relevant to clinical practice.”

Mesothelioma 2017 – The Essential Update
Approved by the Federation of the Royal Colleges of Physicians of the UK for 5 category 1 (external) CPD credits (code 109884)
22nd March 2017 – Wellcome Foundation, London

“This was an excellent day – inspiring and thought provoking; small and friendly; well facilitated expert discussion.”
Research and Representation

The poster abstracts from BTOG 2017 were published in a Supplement to Lung Cancer journal published by Elsevier
Reference: Volume 103, Supplement 1, January 2017, ISSN 0169-5002
http://www.lungcancerjournal.info/issue/S0169-5002(17)X0004-4

During the year BTOG has provided networking opportunities at all educational events for the professional community to collaborate to develop clinical trials and other research. BTOG has continued to work collaboratively with many other organisations, societies and groups; to build close and enduring relationships; and to have mutual memberships to ensure representation.

Both Professor Michael Peake, former long-term BTOG Steering Committee Member and now BTOG Trustee and Dawn Mckinley, BTOG Manager are trustees for Mesothelioma UK. Liz Darlison, Director of Services for Mesothelioma UK is also a former long-term BTOG Steering Committee member. During this year BTOG and Mesothelioma UK held Mesothelioma 2017 – The Essential Update bringing together the multi-disciplinary team, researchers and advocates for mesothelioma.

The IASLC has developed a network of Regents around the world to constitute a Council of Regents responsible for a country or group of countries within a geographical region. The Regents have been appointed by the IASLC board to ensure effective communication between IASLC and the members and potential members of the IASLC in the country for which they have responsibility. IASLC currently has Regent Representatives in 17 regions and covering Medical Oncology, Radiation Oncology, Pulmonology, and Thoracic Surgery and Dr Richard Booton, BTOG Steering Committee member is Regent for UK and Ireland.

European Thoracic Oncology Platform – ETOP promotes the exchange of ideas and research in the field of thoracic malignancies. During this year BTOG has continued as a member group and Dr Sanjay Popat, BTOG Steering Committee Chair sits on the Foundation Council.
BTOG and NCRI are both committed to driving and encouraging the development of clinical trials in thoracic oncology. During this year BTOG Steering Committee Member, Dr Matthew Hatton has been Chair of the NCRI Lung Cancer Clinical Studies Group (CSG) and BTOG Steering Committee Chair, Dr Sanjay Popat has been Chair of the NCRI Lung Cancer CSG Advanced Disease Sub-group. Researchers were invited to submit their proposal for development of a trial for presentation and discussion at the Trials Meeting. A total of 15 proposals were discussed at workshops at the meeting from all the subgroups (Advanced Disease, Mesothelioma, Screening and Early Diagnosis and LOcoRegionalDisease – LORD) and presenters were given constructive feedback. Also, held four collaborative sessions at BTOG 2017 to update on progress for each of the subgroups.

NLCFN provides networking and support to nurses specialising in the care of people with lung cancer and as a multi-disciplinary group, BTOG is committed to including nurses in all that it does. During this year BTOG Steering Committee Members, Helena Stanley and Vanessa Beattie both sat on the NLCFN Committee and Vanessa was Vice-Chair/Chair Elect of NLCFN, ensuring mutual representation on both committees.

The Roy Castle Lung Cancer Foundation’s three key activities are research, support and prevention. During this year working in partnership, BTOG and RCLCF held an ASCO National Update Meeting – the meeting updated on significant data presented at ASCO 2016 held in Chicago 3-7 June 2016 covering Diagnostic, Staging and Screening, Radiotherapy: Radical and Palliative Treatment and Systemic Therapy: Emerging and Palliative Treatment.

The British Thoracic Society (BTS) exists to improve standards of care for people who have respiratory diseases and to support and develop those who provide that care. During this year BTOG and BTS held collaborative sessions at BTS Winter 2016 and BTOG 2017.

Thoracic Alliance for Cancer Trials (TACT) is an international non-profit umbrella organisation for academic groups worldwide, dedicated to thoracic oncology research. As a group that has a focus on, but are not directly involved in, conducting clinical trials in thoracic oncology BTOG is an observer member group and during this year a BTOG steering committee member attended TACT General Assemblies held at ASCO 2016 in June 2016 and at WCLC 2016 in December 2016.
British Thoracic Oncology Group (BTOG)  
ANNUAL REPORT  
April 2016 to March 2017

Guidelines and Articles

• **BTS Guideline for the Investigation and Management of Pleural Mesothelioma**
  
  Professor Corinne Faivre-Finn represented the British Thoracic Oncology Group on the Guideline working group and the document was also circulated for comment to the Steering Committee. The Guideline is expected to be published late 2017.

• **Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors - The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC) and the Association for Molecular Pathology (AMP)**
  
  The British Thoracic Oncology Group steering committee took part in the consultation to revise the 2013 Guideline. The Guideline is expected to be published in 2017.

• **The Royal College of Pathologists Dataset for Lung Cancer Histopathology Reports**

• **The Royal College of Pathologists Dataset for the Histological Reporting of Thymic Epithelial Tumours**
  
  Two datasets were circulated for review and comment to three stakeholder groups and British Thoracic Oncology Group was one of these groups. The Datasets were published in September 2016.

• **Electronic cigarettes: a survey of perceived patient use and attitudes among members of the British Thoracic Oncology Group**
  
  Published May 2016 in Respiratory Research

---

**NICE National Institute for Health and Care Excellence**

BTOG is a recognised body to review NICE appraisals for new drug therapies for thoracic malignancies. This year has seen an unprecedented number of NICE appraisals and BTOG actively participated in all relevant scoping and full appraisals.

- ID935 Alectinib (Alecensa) - Previously treated anaplastic kinase-positive NSCLC
- ID821 Anamorelin - For treating anorexia and cachexia – NSCLC
- ID970 Atezolizumab - Treating locally advanced or metastatic NSCLC lung cancer after platinum-based chemotherapy
- ID865 Crizotinib (Xalkori) - For untreated anaplastic lymphoma kinase-positive advanced NSCLC
- ID1010 TA296 Crizotinib - For the treatment of previously treated NSCLC associated with an anaplastic lymphoma kinase fusion gene
- ID929 Dabrafenib (Portrazza) - For advanced NSCLC, metastatic, squamous
- ID811 Nivolumab (Opdivo) - For previously treated NSCLC, locally advanced or metastatic squamous
- ID880 Pembrolizumab (Keytruda) – NSCLC, advanced, recurrent, PD-L1 positive - after platinum chemotherapy
- ID1005 (TA309) Pemetrexed – For following induction therapy w/pemetrexed/cisplatin non-squamous NSCLC
- ID990 Pembrolizumab (Keytruda) - For untreated PD-L1 positive met NSCLC
- ID838 Ramucirumab (Cymramza) - NSCLC metastatic with docetaxel, after platinum chemotherapy
- DG9 EGFR-TK Mutation Testing in adults with locally advanced or met NSCLC
During this year BTOG has been extremely busy. As well as the practical day to day management of BTOG, I am also responsible for working with the Steering Committee and Board of Trustees to ensure appropriate governance is in place and that effective planning ensures delivery of BTOG’s aims and objectives.

Following registration as a charity we recognised that this is a significant time for BTOG – a time for strategy development, change and to cement BTOG’s position in the thoracic oncology professional network.

I look forward to working with all stakeholders of BTOG and the larger thoracic oncology professional community and I am committed to continue to always be approachable, consistent and professional.

Dawn McKinley
Manager
British Thoracic Oncology Group

BTOG’s Values

- We are committed to achieving our mission and vision.
- We are proud to be an important part of the thoracic oncology professional community.
- We work collaboratively with other groups who in their own ways are also striving to improve outcomes for this group of patients or reduce the prevalence of lung cancer e.g. relating to smoking cessation.
- We listen to our stakeholders to ensure what we do is relevant and effective.
- We maintain a highly professional level of independence from any single external commercial organisation.
- We hold patients at the centre of everything we do.